Patient P-03003

Synthetic patientONX-7 · Day 113 · 35–44 · F · baseline S08Steering view · 3D Open companion preview

Therapy response

Improving

Tolerance

Stable

GI state

Improving

Inflammatory state

Improving

Nutritional resilience

Improving

Discontinuation risk

54%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 ONX-7 started — Baseline state S08
Day 56 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 61 GI-04 recommended — GI Support Protocol GI-04
Day 62 Patient accepted — Started GI-04 in the companion
Day 65 SC-12 recommended — Supportive Compound SC-12
Day 66 Patient accepted — Started SC-12 in the companion
Day 70 No meaningful change — GI Support Protocol GI-04
Day 72 GI symptom burden −10% vs expected — Supportive Compound SC-12
Day 78 Tolerance state changed — Unstable → Improving
Day 80 ME-01 recommended — Monitoring Escalation ME-01
Day 81 Patient accepted — Started ME-01 in the companion
Day 84 Deterioration detected before clinical escalation — Monitoring Escalation ME-01

What changed?

Trajectory began diverging from predicted response on Day 56.

Primary contributors, last 14 days

GI instability-19
Treatment adherence-11
Inflammatory activity-10
Nutritional resilience+8
Toxicity+2

What helped?

GI Support Protocol GI-04Day 61
Result: no meaningful change
Supportive Compound SC-12Day 65
Result: symptom burden −10%
Monitoring Escalation ME-01Day 80
Result: deterioration detected before clinical escalation

LIFE OS recommendation

Dietary Support Protocol NP-02

47%

probability of meaningful tolerance improvement

284 similar trajectories
63% showed improvement
median effect visible after 10 days

Daily trackers

Molecule settings

The trackers this program marks as important, last 14 days vs the 14 before.

Energy level

Daily log

4.6/10

improving · +0.9 vs previous 14 d

Stress level

Daily log

7.3/10

improving · -0.8 vs previous 14 d

Pessimism score

Daily log

6.4/10

improving · -0.6 vs previous 14 d

Sleep quality

Wearable

35/100

improving · +11.9 vs previous 14 d

Libido

Daily log

2.3/10

improving · +0.6 vs previous 14 d

HRV

Wearable

22 ms

improving · +4.2 vs previous 14 d

Toxicity

Blood

41.9/100

improving · -3.6 vs previous 14 d

This trajectory is doing well — what to keep, what to watch

Steering view →

Heading towards restoration · 43 from the failing basin, 44 from restoration.

Good elements to keep

Supportive Compound SC-12
intervention · steering +15.1
Protein (supports)
perturbation · steering +9
Butyrate producers intact
hidden · steering +7.5
GI Support Protocol GI-04
intervention · steering +4.7
Protein
supporter · GI -5.2 next day

Main detractors to watch

FUT2 non-secretor
hidden · steering -10.6
Low microbial diversity
hidden · steering -7.7
Bacteroides fragilis elevated
hidden · steering -7.4
IL6 high-expression variant
hidden · steering -7.3
Histamine load
detractor · GI +3.2 next day
Lactose
detractor · GI +2.6 next day

State influencers · digestive

Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

Protein
-5.2supporter · 95%
Histamine load
+3.2detractor · 94%
Lactose
+2.6detractor · 78%
Dietary fat load
-0.9no signal · 25%
Alcohol
-0.6no signal · 15%
Caffeine
-0.1no signal · 15%

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Inflammatory signalling ↓85
- DNAIL6 -174 variant raises baseline inflammatory tone
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 46
- WearableHRV 22 ms, trending down
Butyrate / short-chain fatty acid production ↓45
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
Autonomic recovery ↑45
- WearableResting HR 79 bpm
- Wearable2,475 steps/day
Mucosal barrier integrity ↓30
- DNAFUT2 non-secretor lowers mucosal fucosylation
Drug metabolism and exposure ↑20
- BloodToxicity index 42

DNA

Fictional pharmacogenomic panel

FUT2 rs601338 AA (non-secretor)
Reduced mucosal fucosylation
IL6 -174 G/C
Higher inflammatory tone
CYP2D6 Normal metabolizer
Expected exposure
MTHFR C677T
Reduced folate turnover

Microbiome

Shannon diversity 2.9 · butyrate capacity 46/100

Akkermansia muciniphilaNormal
Faecalibacterium prausnitziiLow
Bacteroides fragilisHigh
Bifidobacterium longumNormal
EnterobacteriaceaeNormal

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 21 ms
Sleep: 6.9 h
Steps: 2,244
Resting HR: 77 bpm

Daily log: GI score 45, nutritional resilience 47, adherence 40.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Avoid known triggers for now: fried or oily food, dairy, alcohol

What to do

Track each bowel movement today: time, stool form, urgency, overnight waking
A 15-minute walk after lunch
Keep the sleep window steady
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the scheduled dose as agreed with your care team
Electrolyte solution, one sachet after any loose stool
Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-03049	42%	S14	GI-04	improved	49
P-03081	40%	S10	GI-04	improved	53
P-03123	39%	S14	GI-04	improved	50
P-03226	39%	S05	GI-04	improved	43
P-03251	38%	S14	SC-12	improved	54
P-03037	37%	S14	NP-02	improved	43
P-03430	37%	S14	SC-12	improved	45
P-03323	36%	S14	GI-04	improved	48
P-03090	35%	S02	GI-04	improved	48
P-03159	35%	S14	GI-04	improved	37
P-03341	35%	S14	NP-02	improved	49
P-03460	34%	S11	SC-12	improved	46